EMEA publishes guidance on trials in neonates
This article was originally published in SRA
The complexity of anatomic and functional adaptation processes in neonates means that even subtle variations made through the administration of drugs can impede the smooth transition to extrauterine life, the European Medicines Agency (EMEA) says in new guidance on the development of medicinal products for use in the neonatal period1.
You may also be interested in...
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.